ClinicalTrials.gg
RecruitingNCT05875948Updated Oct 3, 2023

Study to Evaluate R2R01 Plus Terlipressin Versus Terlipressin Alone in Patients With Hepatorenal Syndrome

A Phase 2 interventional study of R2R01 and Terlipressin in Hepatorenal Syndrome and Acute Kidney Injury, sponsored by River 2 Renal Corp.. Recruiting at 7 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2023-10-03.

Sponsored by River 2 Renal Corp. · Phase 2, Interventional, and Treatment

From the registry’s dates

  • Primary completion was expected by Dec 2024, 1 year 11 months ago, but the record still lists the study as recruiting.
  • Started Jun 2023; still recruiting 3 years 4 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
95
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 12 studies testing terlipressin in Hepatorenal Syndrome — 1 open to participants now, 1 under way, none of them phase 3. Terlipressin · Hepatorenal Syndrome.

Planned enrollment
5th of 12
95 · median 65
Started
2023
the only one that year
Phase 2
Only one
of the 12
Registered
11th of 12
by date
Lead sponsor
1 of 12
River 2 Renal Corp.

Among the 12 studies testing terlipressin in Hepatorenal Syndrome, this one is the 5th largest by planned enrollment, is the only one that started in 2023, is the only one in phase 2, and was the 11th registered.

Hepatorenal Syndrome

50 studies on the registry are indexed under Hepatorenal Syndrome; 7 are open to participants now.

Browse Hepatorenal Syndrome studies →

Open to participants now

1 of the 12 studies testing terlipressin in Hepatorenal Syndrome is open now, in 1 country.

By country, each count listing its studies:

About terlipressin

Terlipressin: first FDA approval 2022 (TERLIVAZ). What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 6 Hepatorenal Syndrome studies recruiting now, 2 set no upper age limit and 1 stops at 75 or younger; none take children under 18; none take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 12 studies testing terlipressin in Hepatorenal Syndrome, or all of them as a file.
02

Study summary

This study aims to evaluate the safety, tolerability and efficacy of R2R01 combined with terlipressin as compared to terlipressin alone in the treatment of patients with HRS-AKI

Read the detailed description

This is a phase 2 randomized, single-blind, placebo-controlled, two group, multicenter trial preceded by a safety run-in, in patients with Hepatorenal Syndrome (HRS) - Acute Kidney Injury (HRS-AKI).

The study consists of:

A. an Open-Label Safety Run-In Part with 3 Cohorts of patients, followed by

B. a Single-Blind Placebo-Controlled Randomized Part with two Cohorts of patients treated in parallel, and

C. an Open-Label Terlipressin Non-Responder Cohort.

All patients in all Cohorts will be treated with terlipressin, administered as a slow intravenous (IV) bolus 1 mg over 2 minutes every 6 hours (h) to be increased if clinically appropriate to 2.0 mg every 6 h. Terlipressin dosing should continue up to 24 h after achievement of an HRS response (either Partial or Full) based on Serum Creatinine (SCr)/AKI stage or up to day 14.

For those Cohorts where terlipressin will be administered combined with R2R01 (i.e., Cohorts 1, 2, 3, 4, and 6), the first R2R01 administration will commence immediately following the first terlipressin administration. Like terlipressin treatment, R2R01 dosing should continue up to 24 h after achievement of an HRS response (either Partial or Full) based on SCr/AKI stage or up to day 14.

All patients in all Cohorts will be followed for up to 90 days after the first dose of study drug.

This study will be conducted across approximately 25 centers in EU, UK, US, and Canada.

The screening period will occur within 14 days prior to the first dose administration.

The treatment duration is up to 14 days with a follow-up period of approximately 76 days.

The expected total duration of study participation is up to 15 weeks for each subject.

03

Conditions studied

  • Hepatorenal Syndrome
  • Acute Kidney Injury

Keywords

  • HRS-AKI
  • HRS
  • Renal Failure
  • Kidney Failure
  • Single-blind
  • Open-Label
  • Phase 2
  • R2R01
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Patient is able to communicate well with the Investigator, understands and is willing to comply with all requirements of the study, and understands and signs the written form (ICF).
  2. At least 18 years of age.
  3. Cirrhosis and ascites.
  4. AKI stage 2 or 3. AKI defined by any of the following: 1) increase in SCr (SCr) ≥ 0.3 mg/dl (or ≥ 26.5 micromolar/L) within 48 h, or 2) increase ≥ 50% in baseline SCr, which is known or presumed to have occurred within the prior seven days.
  5. QLY SCr ≥ to 1.5 mg/dl.
  6. No sustained improvement in renal function (less than 20% decrease in SCr and SCr => 1.5 mg/dL) after 48 h of diuretic withdrawal and the beginning of plasma volume expansion with albumin.
  7. Female patients as well as female partners of male patients must be willing to avoid pregnancy for the duration of the study (>90 days).

Exclusion criteria

Exclusion Criteria:

  1. Significant co-morbidities that in the opinion of the Investigator would preclude study participation.
  2. QLY SCr level > 5 mg/dL.
  3. AKI stage 1.
  4. ACLF stage 3.
  5. Model for End-Stage Liver Disease (MELD) score >35.
  6. At least one event of large volume paracentesis (LVP) > 4 Liters in the last 4 days before enrollment.
  7. Current or recent (within 4 weeks) treatment with nephrotoxic drugs (e.g., aminoglycosides, amphotericin, cyclosporine, NSAIDS (e.g., ibuprofen, naproxen, celecoxib), significant exposure to radiographic contrast agents (large doses or multiple injections of iodinated contrast media).
  8. Shock (hypovolemic-, cardiogenic-, or vasodilatory/distributive shock) with mean arterial blood pressure (MAP) ≤70 mmHg or systolic blood pressure ≤90 mmHg along with hypoperfusion.
  9. Sepsis or uncontrolled bacterial infection (e.g., persisting bacteremia, persisting ascitic fluid leucocytosis, fever, increasing leucocytosis with vasomotor instability) as measured with the quick sepsis-related organ dysfunction assessment (qSOFA) score.
  10. Fewer than two days of anti-infective therapy for documented or suspected infection.
  11. Superimposed acute liver injury induced by drugs, herbal preparation or dietary supplements, with the exception of alcoholic hepatitis.
  12. Estimated less than 5 days.
  13. Hypoxia (\<90%) or worsening respiratory symptoms.
  14. Proteinuria > 500 mg/day.
  15. Tubular epithelial casts, heme granular casts.
  16. Haematuria or microhaematuria (more than 50 red blood cells per high power field).
  17. Abnormal renal ultra-sonography unless there is a known chronic structural disease (e.g., diabetic or hypertensive nephropathy).
  18. Current or recent (within 4 weeks) renal replacement therapy (RRT).
  19. Severe cardiovascular and pulmonary diseases including, but not limited to, unstable angina, pulmonary edema, congestive heart failure requiring increasing doses of drug therapy, persisting symptomatic peripheral vascular disease, or any other cardiovascular disease judged by the Investigator to be severe.
  20. Transjugular intra-hepatic systemic shunt (TIPS) unless it is known to be non-functioning or occluded.
  21. Ongoing use of vasopressors, unless used for only 48 h before screening; in this case a of 8 h before enrollment will be necessary. Patients receiving midodrine and octreotide may be enrolled but treatment must be discontinued prior to enrollment.
  22. Known allergy or to terlipressin or other component of the study treatment.
  23. Subject is not suitable to participate in the study for any reason (including, but not limited to co-morbidities, history of non-compliance with study visits, procedures, or drug administration) in the opinion of the Investigator.
  24. Females of (those who are not surgically sterilized or for at least 1 year) are excluded from participation in the study unless they agree to use highly effective .
  25. Males who have no sterilization history and whose female partners have child-bearing potential must agree to use a highly effective method of contraception during the period from the time of signing the form (ICF) through 90 days after the last dose of study drug. A male patient must agree to immediately inform the Investigator if his partner becomes pregnant during the study.
Terms in these criteria, in plain language(7)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

Washout period

A planned gap after a treatment, so that its effects can lessen before the study treatment or a study assessment. Ask the study team and the doctor who prescribed it before changing any medicine.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Sequential assignment
Masking
Single (Participant)
Enrollment
95 participants (estimated)

Study arms

  • Experimental
    An Open-Label Safety Run-In Part

    Three initial cohorts (Cohort 1, N=3 patients, Cohorts 2 and 3, N=6 patients, each) will be treated with an open-label combination of terlipressin and R2R01 to ascertain the safety of the combination therapy. A Safety Review Committee (SRC) will review the safety of Cohort 1 patients based on the adverse events and laboratory abnormalities up until Day 14, prior to the start of recruitment of Cohort 2 patients, as well as the safety of Cohorts 1 and 2 patients up until Day 14 prior to the start of recruitment of Cohort 3 patients. Data from all Cohorts 1, 2, and 3 patients up until Day 14 will be reviewed by the SRC before starting the randomized part of the study (Cohorts 4 and 5), so that the SRC can decide and confirm the most appropriate R2R01 dose schedule for patients in Cohorts 4 and 5. Patients enrolled in Cohorts 1, 2, or 3 will remain in their Cohort until study completion (Day 90) or study discontinuation.

    Drug: R2R01 · Drug: Terlipressin

  • Placebo comparator
    Single-blind Placebo-controlled Randomized period

    After conclusion of the open-label safety run-in part, and after the SRC has determined the appropriate R2R01 dose schedule, approximately 80 patients will receive terlipressin and be randomized 1:1 to either R2R01 (Cohort 4) or placebo (Cohort 5). At randomization, patients will be stratified by the presence of systemic inflammatory response syndrome (SIRS), since patients with SIRS have shown a better response to terlipressin than patients without SIRS.

    Drug: R2R01 · Drug: Terlipressin

  • Experimental
    An Open-Label Terlipressin Non-Responder Cohort

    In Cohort 5, if patients do not respond to terlipressin, they must discontinue Cohort 5. After discontinuation, they will be allowed to enter Cohort 6 (Terlipressin Non-Responder Part) to receive R2R01 with the same dosing and schedule as that for Cohort 4. No patient from any Cohort other than Cohort 5 will be allowed to enter Cohort 6.

    Drug: R2R01 · Drug: Terlipressin

Interventions

  • DrugR2R01

    Pharmaceutical form: sterile 2R vials containing 10 mg of R2R01.

  • In the US, terlipressin is supplied as a sterile, preservative-free, lyophilized, white-to- off-white powder for intravenous (IV) administration. Each vial contains 0.85 mg Terlivaz, equivalent to 1 mg terlipressin acetate, and 10.0 mg mannitol. Terlivaz requires reconstituting in saline (5mL). In the EU, terlipressin is supplied in a clear glass vial with 5 ml of injection solution, containing 1 mg terlipressin acetate corresponding to 0.85 mg terlipressin.

06

What researchers measure

Primary outcomes

  1. Safety Evaluation Criteria - Treatment Emergent Adverse Events (TEAEs)

    Safety and tolerability will be assessed by occurrence of TEAEs. Outcome will be reported as the count of participant experiencing TEAEs.

    Time frame: From first dose of study drug to 30 days post last dose

  2. Safety Evaluation Criteria - Change in Weight

    Safety and tolerability will be assessed by change in body weight

    Time frame: Change from screening through Day 30

  3. Safety Evaluation Criteria - Vital Signs - Respiration Rate

    Safety and tolerability will be assessed by change in respiration rate

    Time frame: Change from screening through Day 30

  4. Safety Evaluation Criteria - Vital Signs - Body Temperature

    Safety and tolerability will be assessed by change in body temperature

    Time frame: Change from screening through Day 30

  5. Safety Evaluation Criteria - Vital Signs - Continuous pulse oximetry (SpO2)

    Safety and tolerability will be assessed by change in SpO2

    Time frame: Change from baseline through Day 30

  6. Safety Evaluation Criteria - Vital Signs - Systolic Blood Pressure (SBP)

    Safety and tolerability will be assessed by change in SBP

    Time frame: Change from screening through Day 30

  7. Safety Evaluation Criteria - Vital Signs - Diastolic Blood pressure (DBP)

    Safety and tolerability will be assessed by change in DBP

    Time frame: Change from screening through Day 30

  8. Safety Evaluation Criteria - Vital Signs - Heart Rate (HR)

    Safety and tolerability will be assessed by change in Heart Rate (HR)

    Time frame: Change from screening through Day 30

  9. Safety Evaluation Criteria - ECGs - PR interval

    Safety and tolerability will be assessed by occurrence of ECGs

    Time frame: Change from screening to Day 14 or hospital discharge

  10. Safety Evaluation Criteria - ECGs - RR interval

    Safety and tolerability will be assessed by occurrence of ECGs

    Time frame: Change from screening to Day 14 or hospital discharge

  11. Safety Evaluation Criteria - ECGs - QRS duration

    Safety and tolerability will be assessed by occurrence of ECGs

    Time frame: Change from screening to Day 14 or hospital discharge

  12. Safety Evaluation Criteria - ECGs - QT interval

    Safety and tolerability will be assessed by occurrence of ECGs

    Time frame: Change from screening to Day 14 or hospital discharge

  13. Safety Evaluation Criteria - ECGs - QTcF interval

    Safety and tolerability will be assessed by occurrence of ECGs

    Time frame: Change from screening to Day 14 or hospital discharge

  14. Safety Evaluation Criteria - ECGs - QTcB interval

    Safety and tolerability will be assessed by occurrence of ECGs

    Time frame: Change from screening to Day 14 or hospital discharge

  15. The incidence of Responders

    The incidence of Responders (Established HRS reversal defined as patients with a Full or Partial HRS response (based on SCr/AKI stage) AND are alive without Renal Replacement Therapy (RRT) for at least 30 days after the first dose of study medication), evaluated separately as two different outcome groups and combined. In case of recurrence and retreatment during the first 30 days, the second treatment period will be evaluated for response

    Time frame: 90 days

Secondary outcomes

  1. Mortality Rate

    Number of patients who died at day 30, 60, and 90.

    Time frame: 30, 60, 90 days

  2. Liver Transplant Rates

    Number of patients undergoing a liver transplant at day 30, 60, and 90.

    Time frame: 30, 60, 90 days

07

Study locations

5 of 7 sites recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Jun 2023 (actual). Primary completion is estimated for Dec 2024, 18 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
May 1, 2023
First posted
May 25, 2023
StartActual
Jun 30, 2023
Primary completionEst.
Dec 2024
CompletionEst.
Dec 2024
Last update
Oct 3, 2023
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Oct 3, 2023, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05875948
Lead sponsor
River 2 Renal Corp.
Responsible party
Sponsor
First posted
May 25, 2023
Start date
Jun 30, 2023
Primary completion
Dec 2024 (estimated)
Completion
Dec 2024 (estimated)
Last update
Oct 3, 2023

Study contacts

Guido Magni, MD, PHD
Contact
magniguido@yahoo.com
+41 794563810
Kathie Gabriel, RN, MFT
Contact
kgabriel@narrowrivermgmt.com
610-937-1932

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Terlipressin

Start the discussion